1	5	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Tropism	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	YFV	_	_	NNP	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	humans	_	_	NNS	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	after	_	_	IN	_	_	_	_	_
5	transcutaneous	_	_	JJ	_	_	_	_	_
6	inoculation	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	YFV	_	_	NNP	_	_	_	_	_
9	exhibits	_	_	VBZ	_	_	_	_	_
10	broad	_	_	JJ	_	_	_	_	_
11	patterns	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	tissue	_	_	NN	_	_	_	_	_
14	tropism	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	is	_	_	VBZ	_	_	_	_	_
17	disseminated	_	_	VBN	_	_	_	_	_
18	systemically	_	_	RB	_	_	_	_	_
19	via	_	_	IN	_	_	_	_	_
20	infection	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	multiple	_	_	JJ	_	_	_	_	_
23	white	_	_	JJ	_	_	_	_	_
24	cell	_	_	NN	_	_	_	_	_
25	subsets	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	With	_	_	IN	_	_	_	_	_
2	respect	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	organ	_	_	NN	_	_	_	_	_
5	tropism	_	_	NN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	liver	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	primary	_	_	JJ	_	_	_	_	_
12	target	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	although	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	heart	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	kidneys	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	liver	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	spleen	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	less	_	_	RBR	_	_	_	_	_
26	frequently	_	_	RB	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	brain	_	_	NN	_	_	_	_	_
30	tissue	_	_	NN	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	can	_	_	MD	_	_	_	_	_
33	support	_	_	VB	_	_	_	_	_
34	YFV	_	_	NN	_	_	_	_	_
35	replication	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	natural	_	_	JJ	_	_	_	_	_
3	host	_	_	NN	_	_	_	_	_
4	range	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	YFV	_	_	NNP	_	_	_	_	_
7	includes	_	_	VBZ	_	_	_	_	_
8	humans	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	non-human	_	_	JJ	_	_	_	_	_
11	primates	_	_	NNS	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	mosquitos	_	_	NNS	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Additionally	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	wild	_	_	JJ	_	_	_	_	_
4	animals	_	_	NNS	_	_	_	_	_
5	from	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	diverse	_	_	JJ	_	_	_	_	_
8	orders	_	_	NNS	_	_	_	_	_
9	Artiodactyla	_	_	NNP	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	Carnivora	_	_	NNP	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	superorder	_	_	NN	_	_	_	_	_
15	Xenarthra	_	_	NNP	_	_	_	_	_
16	have	_	_	VBP	_	_	_	_	_
17	been	_	_	VBN	_	_	_	_	_
18	reported	_	_	VBN	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	be	_	_	VB	_	_	_	_	_
21	serologically	_	_	RB	_	_	_	_	_
22	positive	_	_	JJ	_	_	_	_	_
23	for	_	_	IN	_	_	_	_	_
24	anti-YFV	_	_	NN	_	_	_	_	_
25	antibodies	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	elicitation	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	antibody	_	_	NN	_	_	_	_	_
32	responses	_	_	NNS	_	_	_	_	_
33	against	_	_	IN	_	_	_	_	_
34	YFV	_	_	NNP	_	_	_	_	_
35	indicates	_	_	VBZ	_	_	_	_	_
36	a	_	_	DT	_	_	_	_	_
37	potentially	_	_	RB	_	_	_	_	_
38	productive	_	_	JJ	_	_	_	_	_
39	infection	_	_	NN	_	_	_	_	_
40	within	_	_	IN	_	_	_	_	_
41	these	_	_	DT	_	_	_	_	_
42	species	_	_	NNS	_	_	_	_	_
43	,	_	_	,	_	_	_	_	_
44	indicating	_	_	VBG	_	_	_	_	_
45	that	_	_	IN	_	_	_	_	_
46	diverse	_	_	JJ	_	_	_	_	_
47	mammalian	_	_	JJ	_	_	_	_	_
48	species	_	_	NNS	_	_	_	_	_
49	could	_	_	MD	_	_	_	_	_
50	represent	_	_	VB	_	_	_	_	_
51	YFV	_	_	NNP	_	_	_	_	_
52	potential	_	_	JJ	_	_	_	_	_
53	reservoirs	_	_	NNS	_	_	_	_	_
54	(	_	_	-LRB-	_	_	_	_	_
55	see	_	_	VB	_	_	_	_	_
56	Section	_	_	NN	_	_	_	_	_
57	8.3	_	_	CD	_	_	_	_	_
58	)	_	_	-RRB-	_	_	_	_	_
59	.	_	_	.	_	_	_	_	_


1	Mouse	_	_	NN	_	_	_	_	_
2	Models	_	_	NNS	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	YFV	_	_	NNP	_	_	_	_	_


1	YFV	_	_	NN	_	_	_	_	_
2	research	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	currently	_	_	RB	_	_	_	_	_
5	limited	_	_	VBN	_	_	_	_	_
6	as	_	_	IN	_	_	_	_	_
7	it	_	_	PRP	_	_	_	_	_
8	remains	_	_	VBZ	_	_	_	_	_
9	challenging	_	_	JJ	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	expensive	_	_	JJ	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	establish	_	_	VB	_	_	_	_	_
14	workflows	_	_	NNS	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	non-human	_	_	JJ	_	_	_	_	_
17	primates	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	While	_	_	IN	_	_	_	_	_
2	YFV	_	_	NNP	_	_	_	_	_
3	has	_	_	VBZ	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	limited	_	_	JJ	_	_	_	_	_
6	host	_	_	NN	_	_	_	_	_
7	species-tropism	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	artificial	_	_	JJ	_	_	_	_	_
10	infection	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	laboratory	_	_	NN	_	_	_	_	_
13	mice	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	hamsters	_	_	NNS	_	_	_	_	_
16	is	_	_	VBZ	_	_	_	_	_
17	possible	_	_	JJ	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	although	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	course	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	disease	_	_	NN	_	_	_	_	_
24	differs	_	_	VBZ	_	_	_	_	_
25	from	_	_	IN	_	_	_	_	_
26	that	_	_	DT	_	_	_	_	_
27	observed	_	_	VBN	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	humans	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Nevertheless	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	number	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	studies	_	_	NNS	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	genetically	_	_	RB	_	_	_	_	_
9	modified	_	_	VBN	_	_	_	_	_
10	or	_	_	CC	_	_	_	_	_
11	humanized	_	_	VBN	_	_	_	_	_
12	mice	_	_	NNS	_	_	_	_	_
13	have	_	_	VBP	_	_	_	_	_
14	yielded	_	_	VBN	_	_	_	_	_
15	insights	_	_	NNS	_	_	_	_	_
16	into	_	_	IN	_	_	_	_	_
17	YFV	_	_	NNP	_	_	_	_	_
18	infection	_	_	NN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	dissemination	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	vivo	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Single	_	_	JJ	_	_	_	_	_
2	cell-tracking	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	YFV-17D	_	_	NN	_	_	_	_	_
5	dissemination	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	different	_	_	JJ	_	_	_	_	_
8	mouse	_	_	NN	_	_	_	_	_
9	models	_	_	NNS	_	_	_	_	_
10	identified	_	_	VBN	_	_	_	_	_
11	novel	_	_	JJ	_	_	_	_	_
12	YFV	_	_	NN	_	_	_	_	_
13	replication	_	_	NN	_	_	_	_	_
14	reservoirs	_	_	NNS	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	secondary	_	_	JJ	_	_	_	_	_
17	lymphoid	_	_	NN	_	_	_	_	_
18	compartments	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	with	_	_	IN	_	_	_	_	_
21	hematopoietic	_	_	JJ	_	_	_	_	_
22	STAT1	_	_	NN	_	_	_	_	_
23	knockout	_	_	NN	_	_	_	_	_
24	increasing	_	_	VBG	_	_	_	_	_
25	virus-induced	_	_	JJ	_	_	_	_	_
26	pathogenicity	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Double-humanized	_	_	JJ	_	_	_	_	_
2	mice	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	developed	_	_	VBN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	possessing	_	_	VBG	_	_	_	_	_
8	both	_	_	CC	_	_	_	_	_
9	human	_	_	JJ	_	_	_	_	_
10	immune	_	_	JJ	_	_	_	_	_
11	systems	_	_	NNS	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	hepatocytes	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	these	_	_	DT	_	_	_	_	_
17	animals	_	_	NNS	_	_	_	_	_
18	represent	_	_	VBP	_	_	_	_	_
19	ideal	_	_	JJ	_	_	_	_	_
20	tools	_	_	NNS	_	_	_	_	_
21	for	_	_	IN	_	_	_	_	_
22	monitoring	_	_	VBG	_	_	_	_	_
23	systemic	_	_	JJ	_	_	_	_	_
24	YFV	_	_	NN	_	_	_	_	_
25	infection	_	_	NN	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	vivo	_	_	NN	_	_	_	_	_
28	as	_	_	IN	_	_	_	_	_
29	both	_	_	DT	_	_	_	_	_
30	compartments	_	_	NNS	_	_	_	_	_
31	are	_	_	VBP	_	_	_	_	_
32	permissive	_	_	JJ	_	_	_	_	_
33	for	_	_	IN	_	_	_	_	_
34	YFV	_	_	NNP	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	hepatotropism	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	YFV	_	_	NN	_	_	_	_	_
7	can	_	_	MD	_	_	_	_	_
8	also	_	_	RB	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	neurotropic	_	_	JJ	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	rodents	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	primates	_	_	NNS	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	humans	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	contrast	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	polio	_	_	NN	_	_	_	_	_
5	virus	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	reovirus	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	which	_	_	WDT	_	_	_	_	_
10	infect	_	_	VBP	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	brain	_	_	NN	_	_	_	_	_
13	via	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	CNS	_	_	NNP	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	YFV-17D	_	_	NNP	_	_	_	_	_
18	infects	_	_	VBZ	_	_	_	_	_
19	brain	_	_	NN	_	_	_	_	_
20	tissue	_	_	NN	_	_	_	_	_
21	by	_	_	IN	_	_	_	_	_
22	crossing	_	_	VBG	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	blood-brain	_	_	NN	_	_	_	_	_
25	barrier	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	mouse-neurovirulent	_	_	JJ	_	_	_	_	_
3	strain	_	_	NN	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	SPYF	_	_	NNP	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	based	_	_	VBN	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	Porterfield	_	_	NNP	_	_	_	_	_
11	17D	_	_	NNP	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	PYF17D	_	_	NNP	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	strain	_	_	NN	_	_	_	_	_
16	was	_	_	VBD	_	_	_	_	_
17	derived	_	_	VBN	_	_	_	_	_
18	by	_	_	IN	_	_	_	_	_
19	additional	_	_	JJ	_	_	_	_	_
20	passaging	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	SCID	_	_	NN	_	_	_	_	_
23	mice	_	_	NNS	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	exhibiting	_	_	VBG	_	_	_	_	_
26	enhanced	_	_	VBN	_	_	_	_	_
27	neurovirulence	_	_	NN	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	neuroinvasiveness	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	enhanced	_	_	VBN	_	_	_	_	_
3	neurotopism	_	_	NN	_	_	_	_	_
4	was	_	_	VBD	_	_	_	_	_
5	correlated	_	_	VBN	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	13	_	_	CD	_	_	_	_	_
8	amino	_	_	JJ	_	_	_	_	_
9	acid	_	_	NN	_	_	_	_	_
10	substitutions	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	five	_	_	CD	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	which	_	_	WDT	_	_	_	_	_
15	were	_	_	VBD	_	_	_	_	_
16	located	_	_	VBN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	E	_	_	NN	_	_	_	_	_
20	protein	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Arboviruses	_	_	NNS	_	_	_	_	_
2	can	_	_	MD	_	_	_	_	_
3	encounter	_	_	VB	_	_	_	_	_
4	dissemination	_	_	NN	_	_	_	_	_
5	barriers	_	_	NNS	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	mosquitos	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	restricting	_	_	VBG	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	spreading	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	virus	_	_	NN	_	_	_	_	_
15	within	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	vector	_	_	NN	_	_	_	_	_
18	species	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	include	_	_	VBP	_	_	_	_	_
3	innate	_	_	JJ	_	_	_	_	_
4	immunity	_	_	NN	_	_	_	_	_
5	related	_	_	VBN	_	_	_	_	_
6	pathways	_	_	NNS	_	_	_	_	_
7	as	_	_	RB	_	_	_	_	_
8	well	_	_	RB	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	physical	_	_	JJ	_	_	_	_	_
11	tissue	_	_	NN	_	_	_	_	_
12	barriers	_	_	NNS	_	_	_	_	_
13	associated	_	_	VBN	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	midgut	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	salivary	_	_	JJ	_	_	_	_	_
19	glands	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	while	_	_	IN	_	_	_	_	_
4	patterns	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	YFV-17D	_	_	NN	_	_	_	_	_
7	dissemination	_	_	NN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	immunocompetent	_	_	JJ	_	_	_	_	_
10	mice	_	_	NNS	_	_	_	_	_
11	were	_	_	VBD	_	_	_	_	_
12	restricted	_	_	VBN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	infection	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	IFNAR	_	_	NNP	_	_	_	_	_
17	knockout	_	_	NN	_	_	_	_	_
18	mice	_	_	NNS	_	_	_	_	_
19	resulted	_	_	VBD	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	broad	_	_	JJ	_	_	_	_	_
22	dissemination	_	_	NN	_	_	_	_	_
23	preceding	_	_	VBG	_	_	_	_	_
24	viral	_	_	JJ	_	_	_	_	_
25	clearance	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	indicating	_	_	VBG	_	_	_	_	_
28	that	_	_	IN	_	_	_	_	_
29	no	_	_	DT	_	_	_	_	_
30	barriers	_	_	NNS	_	_	_	_	_
31	to	_	_	TO	_	_	_	_	_
32	dissemination	_	_	NN	_	_	_	_	_
33	exist	_	_	VBP	_	_	_	_	_
34	in	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	absence	_	_	NN	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	type	_	_	NN	_	_	_	_	_
39	I	_	_	PRP	_	_	_	_	_
40	IFN	_	_	NNP	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	while	_	_	IN	_	_	_	_	_
4	I	_	_	PRP	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	II	_	_	NNP	_	_	_	_	_
7	type	_	_	NN	_	_	_	_	_
8	IFNs	_	_	NNP	_	_	_	_	_
9	contribute	_	_	VBP	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	control	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	YFV-17D	_	_	NN	_	_	_	_	_
14	infection	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	type	_	_	NN	_	_	_	_	_
17	III	_	_	NNP	_	_	_	_	_
18	IFN	_	_	NN	_	_	_	_	_
19	was	_	_	VBD	_	_	_	_	_
20	demonstrated	_	_	VBN	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	have	_	_	VB	_	_	_	_	_
23	immunomodulatory	_	_	JJ	_	_	_	_	_
24	functions	_	_	NNS	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	was	_	_	VBD	_	_	_	_	_
27	protective	_	_	JJ	_	_	_	_	_
28	against	_	_	IN	_	_	_	_	_
29	YFV-17D	_	_	NN	_	_	_	_	_
30	neuroinvasion	_	_	NN	_	_	_	_	_
31	in	_	_	IN	_	_	_	_	_
32	mouse	_	_	NN	_	_	_	_	_
33	models	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	YFD-17D	_	_	JJ	_	_	_	_	_
2	infection	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	IFN-α/β	_	_	NN	_	_	_	_	_
5	receptor	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	STAT1	_	_	NN	_	_	_	_	_
8	signaling	_	_	VBG	_	_	_	_	_
9	molecule	_	_	NN	_	_	_	_	_
10	deficient	_	_	JJ	_	_	_	_	_
11	mice	_	_	NNS	_	_	_	_	_
12	resulted	_	_	VBD	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	systemic	_	_	JJ	_	_	_	_	_
15	viscerotropic	_	_	JJ	_	_	_	_	_
16	infection	_	_	NN	_	_	_	_	_
17	:	_	_	:	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	course	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	disease	_	_	NN	_	_	_	_	_
22	which	_	_	WDT	_	_	_	_	_
23	resembles	_	_	VBZ	_	_	_	_	_
24	that	_	_	DT	_	_	_	_	_
25	observed	_	_	VBN	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	humans	_	_	NNS	_	_	_	_	_
28	rather	_	_	RB	_	_	_	_	_
29	than	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	typical	_	_	JJ	_	_	_	_	_
32	encephalitic	_	_	JJ	_	_	_	_	_
33	disease	_	_	NN	_	_	_	_	_
34	course	_	_	NN	_	_	_	_	_
35	commonly	_	_	RB	_	_	_	_	_
36	reported	_	_	VBN	_	_	_	_	_
37	for	_	_	IN	_	_	_	_	_
38	mice	_	_	NNS	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Finally	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	while	_	_	IN	_	_	_	_	_
4	many	_	_	JJ	_	_	_	_	_
5	flaviviruses	_	_	NNS	_	_	_	_	_
6	share	_	_	VBP	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	common	_	_	JJ	_	_	_	_	_
9	ability	_	_	NN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	antagonize	_	_	VB	_	_	_	_	_
12	IFN	_	_	NNP	_	_	_	_	_
13	signaling	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	therefore	_	_	RB	_	_	_	_	_
16	enhance	_	_	VB	_	_	_	_	_
17	viral	_	_	JJ	_	_	_	_	_
18	replication	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	YFV	_	_	NNP	_	_	_	_	_
22	NS5	_	_	NNP	_	_	_	_	_
23	is	_	_	VBZ	_	_	_	_	_
24	unable	_	_	JJ	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	bind	_	_	VB	_	_	_	_	_
27	murine	_	_	NN	_	_	_	_	_
28	STAT2	_	_	NN	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	contrast	_	_	NN	_	_	_	_	_
32	to	_	_	TO	_	_	_	_	_
33	ZIKV	_	_	NNP	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	DENV	_	_	NNP	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	is	_	_	VBZ	_	_	_	_	_
38	unable	_	_	JJ	_	_	_	_	_
39	to	_	_	TO	_	_	_	_	_
40	engage	_	_	VB	_	_	_	_	_
41	human	_	_	JJ	_	_	_	_	_
42	STAT2	_	_	NN	_	_	_	_	_
43	in	_	_	IN	_	_	_	_	_
44	murine	_	_	NN	_	_	_	_	_
45	cells	_	_	NNS	_	_	_	_	_
46	.	_	_	.	_	_	_	_	_


1	Murine	_	_	NNP	_	_	_	_	_
2	STAT2	_	_	NNP	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	demonstrated	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	repress	_	_	VB	_	_	_	_	_
7	YFV	_	_	NN	_	_	_	_	_
8	replication	_	_	NN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	murine	_	_	NN	_	_	_	_	_
11	cells	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	which	_	_	WDT	_	_	_	_	_
14	was	_	_	VBD	_	_	_	_	_
15	correlated	_	_	VBN	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	an	_	_	DT	_	_	_	_	_
18	absence	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	IFN-α/β-mediated	_	_	JJ	_	_	_	_	_
21	NS5	_	_	NN	_	_	_	_	_
22	ubiquitination	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Together	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	these	_	_	DT	_	_	_	_	_
4	mouse	_	_	NN	_	_	_	_	_
5	studies	_	_	NNS	_	_	_	_	_
6	enhance	_	_	VBP	_	_	_	_	_
7	our	_	_	PRP$	_	_	_	_	_
8	understanding	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	YFV	_	_	NN	_	_	_	_	_
11	dissemination	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	host	_	_	NN	_	_	_	_	_
14	control	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	vivo	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	findings	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	useful	_	_	JJ	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	development	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	next	_	_	JJ	_	_	_	_	_
11	generation	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	small	_	_	JJ	_	_	_	_	_
14	animal	_	_	NN	_	_	_	_	_
15	disease	_	_	NN	_	_	_	_	_
16	models	_	_	NNS	_	_	_	_	_
17	for	_	_	IN	_	_	_	_	_
18	YFV	_	_	NNP	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	which	_	_	WDT	_	_	_	_	_
21	should	_	_	MD	_	_	_	_	_
22	endeavor	_	_	VB	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	recapitulate	_	_	VB	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	disease	_	_	NN	_	_	_	_	_
27	course	_	_	NN	_	_	_	_	_
28	seen	_	_	VBN	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	humans	_	_	NNS	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	generation	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	an	_	_	DT	_	_	_	_	_
7	immunocompetent	_	_	JJ	_	_	_	_	_
8	mouse	_	_	NN	_	_	_	_	_
9	model	_	_	NN	_	_	_	_	_
10	would	_	_	MD	_	_	_	_	_
11	be	_	_	VB	_	_	_	_	_
12	beneficial	_	_	JJ	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	which	_	_	WDT	_	_	_	_	_
15	could	_	_	MD	_	_	_	_	_
16	be	_	_	VB	_	_	_	_	_
17	realized	_	_	VBN	_	_	_	_	_
18	by	_	_	IN	_	_	_	_	_
19	knocking	_	_	VBG	_	_	_	_	_
20	out	_	_	RP	_	_	_	_	_
21	downstream	_	_	JJ	_	_	_	_	_
22	specific	_	_	JJ	_	_	_	_	_
23	anti-YFV	_	_	JJ	_	_	_	_	_
24	effectors	_	_	NNS	_	_	_	_	_
25	that	_	_	WDT	_	_	_	_	_
26	directly	_	_	RB	_	_	_	_	_
27	inhibit	_	_	VBP	_	_	_	_	_
28	differential	_	_	JJ	_	_	_	_	_
29	aspects	_	_	NNS	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	YFV	_	_	NN	_	_	_	_	_
33	lifecycle	_	_	NN	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	rather	_	_	RB	_	_	_	_	_
36	than	_	_	IN	_	_	_	_	_
37	upstream	_	_	JJ	_	_	_	_	_
38	master-regulators	_	_	NNS	_	_	_	_	_
39	of	_	_	IN	_	_	_	_	_
40	the	_	_	DT	_	_	_	_	_
41	antiviral	_	_	JJ	_	_	_	_	_
42	response	_	_	NN	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	Screening	_	_	VBG	_	_	_	_	_
2	approaches	_	_	NNS	_	_	_	_	_
3	could	_	_	MD	_	_	_	_	_
4	identify	_	_	VB	_	_	_	_	_
5	such	_	_	JJ	_	_	_	_	_
6	factors	_	_	NNS	_	_	_	_	_
7	.	_	_	.	_	_	_	_	_

